Article
Oncology
Dorthe Masemann, Ramona Meissner, Tanja Schied, Brian D. Lichty, Ulf R. Rapp, Viktor Wixler, Stephan Ludwig
Summary: The study demonstrated the oncolytic and immunomodulatory efficacy of low-pathogenic influenza A viruses (IAVs) against NSCLCs in mouse models. Combining IAV infection with a novel B7-H3 immune-checkpoint inhibitor (ICI) resulted in significantly improved oncolysis of existing tumors. Individualized therapy with synergistically acting oncolytic IAV and B7-H3 ICI may represent an innovative approach to target NSCLCs resistant to approved ICIs in patients.
Article
Oncology
Jamile Ramos da Silva, Ana Carolina Ramos Moreno, Natiely Silva Sales, Mariangela de Oliveira Silva, Luana R. M. M. Aps, Bruna F. M. M. Porchia, Karine Bitencourt Rodrigues, Natalia Cestari Moreno, Alexia Adrianne Venceslau-Carvalho, Carlos Frederico M. Menck, Mariana de Oliveira Diniz, Luis Carlos de Souza Ferreira
Summary: The combination of Gem and active immunotherapy demonstrates synergistic antitumor effects, providing evidence for a new and feasible chemoimmunotherapeutic strategy in cancer treatment.
Article
Immunology
Claire Olingy, Ahmad Alimadadi, Daniel J. Araujo, David Barry, Norma A. Gutierrez, Max Hardy Werbin, Edurne Arriola, Sandip Pravin Patel, Christian H. Ottensmeier, Huy Q. Dinh, Catherine C. Hedrick
Summary: This study revealed the correlation between specific monocyte markers and the responsiveness to anti-PD-1 therapy in patients with non-small cell lung carcinoma (NSCLC), providing a potential predictive tool for patient response to anti-PD-1 treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Yanan Gao, Maojun You, Junliang Fu, Meijie Tian, Xinyue Zhong, Chengzhi Du, Zhixian Hong, Zhenyu Zhu, Junliang Liu, Geoffrey J. Markowitz, Fu-Sheng Wang, Pengyuan Yang
Summary: CCR4(+) Tregs play a critical role in hepatitis B-associated hepatocellular carcinoma, contributing to immunotherapy resistance and T cell suppression. Targeting CCR4(+) Tregs can help overcome sorafenib resistance and enhance antitumor immunity by inhibiting their accumulation in the tumor microenvironment and disrupting their stem-like properties.
JOURNAL OF HEPATOLOGY
(2022)
Review
Oncology
Hongchao Tang, Hao Li, Zhijun Sun
Summary: Immunotherapy is a promising breakthrough in cancer treatment, with immune checkpoint blockade showing positive clinical responses in different cancer types. However, the clinical efficacy of ICB is limited in some patients due to the immunosuppressive tumor microenvironment and the role of MDSCs. A combined treatment strategy using MDSC inhibitors and ICB is being proposed to enhance the antitumor efficacy.
CANCER BIOLOGY & MEDICINE
(2021)
Review
Oncology
Christopher Groth, Rebekka Weber, Samantha Lasser, Feyza Gul Ozbay, Annina Kurzay, Vera Petrova, Peter Altevogt, Jochen Utikal, Viktor Umansky
Summary: This review summarizes the origin of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) and their relation to classical neutrophils, outlining their metastasis promoting features and promising strategies for targeting them to enhance the efficacy of cancer immunotherapy.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Cell Biology
Filippos Koinis, Anastasia Xagara, Evangelia Chantzara, Vassiliki Leontopoulou, Chrissovalantis Aidarinis, Athanasios Kotsakis
Summary: This article reviews the research progress on mechanisms involved in the response or resistance to immune checkpoint blockade in prostate cancer (PCa). Myeloid-derived suppressor cells (MDSCs) have been identified as a major mediator of immunosuppression in the tumor microenvironment and strategies to enhance anti-tumor immune response via MDSC targeting are being explored. The article summarizes the current methodologies for phenotypic and metabolic characterization of MDSCs in PCa and discusses their potential impact on clinical outcomes. Additionally, emerging strategies for therapeutically targeting MDSCs are briefly discussed.
Article
Immunology
Glenn F. van Wigcheren, Daphne Roelofs, Carl G. Figdor, Georgina Florez-Grau
Summary: Current treatments for autoimmune diseases involve long-term drug regimens that broadly dampen immune responses, leading to severe side effects and creating a need for safer and more effective therapy. Cell-based immunotherapy using tolerogenic CD14+ myeloid cells offers a promising alternative, with different cell types having distinct cellular properties and immunosuppressive mechanisms. However, each cell type faces unique challenges in development towards immunotherapy, highlighting the potential benefits and risks of novel cell-based therapies for autoimmune diseases.
JOURNAL OF AUTOIMMUNITY
(2021)
Article
Immunology
Supitcha Kamolratanakul, Punnee Pitisuttithum
Summary: Human papillomavirus (HPV) is the most common sexually transmitted infection, with 15 HPV types related to various cancers. HPV vaccines have been proven to be safe and highly effective in preventing HPV infections and associated cancers, especially among young women. The different types of HPV vaccines have shown similar efficacy in protecting against certain HPV types, with the nonavalent vaccine offering additional protection against more types. HPV vaccination has also been shown to provide herd protection and reduce the prevalence of HPV-related cancers.
Review
Immunology
Ya-Jui Lin, Caren Yu-Ju Wu, Janet Yuling Wu, Michael Lim
Summary: Glioblastoma is a highly aggressive glioma with resistance to immunotherapy, primarily due to the unique immune environment. Myeloid cells play a significant role in the glioma microenvironment and reprogramming them has emerged as a revolutionary immunotherapy for glioma treatment. This article provides a detailed classification and analysis of myeloid cells in glioma TME, aiming to offer new insights and therapeutic approaches for improving treatment efficacy in glioma patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Hong Cao, Chen Ni, Le Han, Ruoqi Wang, Rosel Blasig, Reiner Haseloff, Yue Qin, Jie Lan, Xiaohan Lou, Pan Ma, Xiaohan Yao, Linlin Wang, Fei Wang, Linyu Zhu, Ningjing Lei, Ingolf E. Blasig, Zhihai Qin
Summary: This study found that the absence of tight junction protein Claudin-12 (Cldn12) inhibited the growth of transplanted tumors and reduced the accumulation of myeloid-derived suppressor cells (MDSCs) within tumors, resulting in increased anti-tumor immune responses. The study also revealed that expression of Cldn12 on the cell surface of both MDSCs and endothelial cells (EC) is necessary for MDSCs to cross tumor vascular ECs. Therefore, Cldn12 shows promise as a target for restoring anti-tumor response by interfering with MDSCs transendothelial migration.
Review
Biochemistry & Molecular Biology
Takayuki Morimoto, Tsutomu Nakazawa, Ryosuke Maeoka, Ichiro Nakagawa, Takahiro Tsujimura, Ryosuke Matsuda
Summary: Glioblastoma (GBM) is an aggressive and malignant brain tumor with poor prognosis. Various treatment strategies have been explored, including immunotherapies. However, current immunotherapies mainly based on T cells have not achieved satisfactory outcomes. This review focuses on the potential of NK cell-based immunotherapy as a novel treatment strategy for GBM.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Immunology
Celine Blaye, Thomas Boyer, Florent Peyraud, Charlotte Domblides, Nicolas Larmonier
Summary: Breast cancers are often associated with an immunosuppressive microenvironment, and myeloid cells play a major role in this tumor-promoting environment. Besides their immunosuppressive properties, breast cancer-induced myeloid cells also have a broad range of non-immunological tumor-promoting functions. However, there are difficulties and challenges in distinguishing specific subsets of these cells, hindering their selective targeting and use as potential biomarkers.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Yao Tang, Cong Zhou, Qingli Li, Xiaojiao Cheng, Tinglei Huang, Fuli Li, Lina He, Baiweng Zhang, Shuiping Tu
Summary: This study highlights the potential of combining PD-L1 blockade therapy with agonistic anti-DR5 antibody to target MDSCs in gastric and colon cancers. Targeting DR5 effectively depleted MDSCs, increased CD8(+) T lymphocytes in tumors, and showed synergistic antitumor effects when combined with anti-PD-L1 antibody. The combination therapy also induced sustained memory immunity and enhanced CD8(+) T-cell infiltration and activation in tumors, resulting in significant tumor growth suppression and prolonged survival in mice.
Review
Pharmacology & Pharmacy
Shih-Cheng Pao, Mu-Tzu Chu, Shuen-Iu Hung
Summary: Cancer immunotherapy has become indispensable in cancer treatment, with a focus on targeting tumor-specific antigens or neoantigens. Advanced technologies have allowed for the identification and application of neoantigens in cancer vaccines. Therapeutic vaccines have shown success in activating the immune system to kill cancer cells.
Article
Oncology
David Crottes, Raphael Rapetti-Mauss, Francisca Alcaraz-Perez, Melanie Tichet, Giuseppina Gariano, Sonia Martial, Helene Guizouarn, Bernard Pellissier, Agnes Loubat, Alexandra Popa, Agnes Paquet, Marco Presta, Sophie Tartare-Deckert, Maria Luisa Cayuela, Patrick Martin, Franck Borgese, Olivier Soriani
Article
Biochemical Research Methods
L. Tauzin, V. Campos, M. Tichet
Article
Oncology
Robin Didier, Aude Mallavialle, Rania Ben Jouira, Marie Angela Domdom, Melanie Tichet, Patrick Auberger, Frederic Luciano, Mickael Ohanna, Sophie Tartare-Deckert, Marcel Deckert
MOLECULAR CANCER THERAPEUTICS
(2018)
Article
Oncology
Gabriele Galliverti, Melanie Tichet, Sonia Domingos-Pereira, Sylvie Hauert, Denise Nardelli-Haefliger, Melody A. Swartz, Douglas Hanahan, Stephan Wullschleger
CANCER IMMUNOLOGY RESEARCH
(2018)
Article
Oncology
Terry R. Medler, Dhaarini Murugan, Wesley Horton, Sushil Kumar, Tiziana Cotechini, Alexandra M. Forsyth, Patrick Leyshock, Justin J. Leitenberger, Molly Kulesz-Martin, Adam A. Margolin, Zena Werb, Lisa M. Coussens
Article
Cell Biology
Iacovos P. Michael, Sadegh Saghafinia, Melanie Tichet, Nadine Zangger, Ilaria Marinoni, Aurel Perren, Douglas Hanahan
DEVELOPMENTAL CELL
(2019)
Article
Oncology
Sadegh Saghafinia, Krisztian Homicsko, Annunziata Di Domenico, Stephan Wullschleger, Aurel Perren, Ilaria Marinoni, Giovanni Ciriello, Iacovos P. Michael, Douglas Hanahan
Summary: Pancreatic neuroendocrine tumors consist of two subtypes: relatively benign islet tumors and invasive, metastasis-like primary tumors. The aggressive MLP tumors are revealed to arise from dedifferentiation of IT tumors along the developmental pathway of islet beta cells. This dedifferentiation step, separate from proliferation, leads to increased HMGB3 expression and is associated with higher-grade tumors and worse survival in patients.
Article
Oncology
Colin J. Daniel, Carl Pelz, Xiaoyan Wang, Michael W. Munks, Aaron Ko, Dhaarini Murugan, Sarah A. Byers, Eleonora Juarez, Karyn L. Taylor, Guang Fan, Lisa M. Coussens, Jason M. Link, Rosalie C. Sears
Summary: This study highlights the importance of regulated phosphorylation of MYC at T58 and S62 in T-cell transformation, and reveals differential effects of MYC lacking phosphorylation on T-cell development and lymphomagenesis.
MOLECULAR CANCER RESEARCH
(2022)
Article
Oncology
Agnieszka Chryplewicz, Julie Scotton, Melanie Tichet, Anoek Zomer, Ksenya Shchors, Johanna A. Joyce, Krisztian Homicsko, Douglas Hanahan
Summary: This study demonstrates the potential of combination therapy targeting different vulnerabilities in the tumor microenvironment to effectively treat glioblastoma.
Article
Multidisciplinary Sciences
Laura Codarri Deak, Valeria Nicolini, Masao Hashimoto, Maria Karagianni, Petra C. Schwalie, Laura Lauener, Eleni Maria Varypataki, Marine Richard, Esther Bommer, Johannes Sam, Stefanie Joller, Mario Perro, Floriana Cremasco, Leo Kunz, Emilio Yanguez, Tamara Husser, Ramona Schlenker, Marisa Mariani, Vinko Tosevski, Sylvia Herter, Marina Bacac, Inja Waldhauer, Sara Colombetti, Xavier Gueripel, Stephan Wullschleger, Melanie Tichet, Douglas Hanahan, Haydn T. Kissick, Stephane Leclair, Anne Freimoser-Grundschober, Stefan Seeber, Volker Teichgraber, Rafi Ahmed, Christian Klein, Pablo Umana
Summary: The study shows that PD1-IL2v can induce the differentiation of stem-like CD8(+) T cells into better effector cells by binding to PD-1, without the need for CD25 binding. PD1-IL2v has superior efficacy compared to PD-1 or PD-L1 blocking antibodies, as it avoids the accumulation of terminally differentiated and exhausted T cells.
Article
Immunology
Melanie Tichet, Stephan Wullschleger, Agnieszka Chryplewicz, Nadine Fournier, Rachel Marcone, Annamaria Kauzlaric, Krisztian Homicsko, Laura Codarri Deak, Pablo Umana, Christian Klein, Douglas Hanahan
Summary: PD1-IL2v is an engineered immunocytokine that delivers IL2v precisely to PD-1+ T cells in the tumor microenvironment, resulting in infiltration by stem-like CD8+ T cells and enhanced tumor regression and survival in mice. Combining PD1-IL2v with anti-PD-L1 improves therapeutic efficacy by reprogramming tumor-associated macrophages and enhancing T cell receptor immune repertoire diversity. These findings support the clinical evaluation of PD1-IL2v and anti-PD-L1 combination therapy in immunotherapy-resistant tumors infiltrated with PD-1+ stem-like T cells.